Skip to main content
. Author manuscript; available in PMC: 2023 Mar 15.
Published in final edited form as: Biomater Sci. 2023 Mar 14;11(6):2065–2079. doi: 10.1039/d2bm00819j

Fig. 1.

Fig. 1

Challenges associated with passive immunization prophylaxis and the desired attributes for an ideal antibody formulation to enable effective prophylaxis. a) Passive immunization provides protection against infectious disease through direct administration of broadly neutralizing antibodies (bnAbs). b) Current bnAbs exhibit poor pharmacokinetics and require multiple doses to maintain a protective titer; in addition, c) most bnAbs are administered by IV infusion, which limits the feasibility of the treatment. d) Comparing current formulation limitations with those of an ideal formulation, e) a subcutaneous depot containing bnAbs emerges as a potential solution to current formulation challenges.